Macular Degeneration: all 1,490 studies
Page 7 of 15. Open to participants first (208), then studies with results posted, then the rest; newest registration first within each.
- QA108 Phase II Study in Subjects With Intermediate Age-Related Macular DegenerationCompletedNCT05562219Phase 2
- Assessment Of Diabetic Maculopathy Changes After Phacoemulsification by Using Optical Coherence TomographyStatus unknownNCT05547789
- The Role of Loteprednol in Reducing Post-Intravitreal Injection Related PainCompletedNCT05542381Not applicable
- Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMDStatus unknownNCT05539235Phase 2/3
- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]Active, not recruitingNCT05536973Phase 2
- Effect of Corona Virus on Intravitreal InjectionsStatus unknownNCT05494775Not applicable
- TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular DegenerationActive, not recruitingNCT05461339Phase 3
- Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)CompletedNCT05447650Not applicable
- Validation of Bulbicam for DR- and AMD-patientsCompletedNCT05441072
- Factors in Learning And Plasticity: Healthy VisionActive, not recruitingNCT05439759Not applicable
- Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular DegenerationCompletedNCT05439629Phase 3
- Effectiveness of Prism Spectacles in Patients With Age Related Macular DegenerationCompletedNCT05437302Not applicable
- Patient-centred Smartphone AI for Protecting Vision in Macular DiseaseStatus unknownNCT05433766
- Assessing the Quality of Life and Social Support in Age-Related Macular Degeneration PatientsCompletedNCT05427994
- Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt DiseaseCompletedNCT05417126Phase 2
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDActive, not recruitingNCT05407636Phase 3
- A Study of Longer Interval of IVT IBI302 in Subjects With nAMDCompletedNCT05403749Phase 2
- Oral Postbiotics in Patients With Macular AtrophyStatus unknownNCT05391074Not applicable
- Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DMEActive, not recruitingNCT05387837Phase 2
- Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationActive, not recruitingNCT05380492Phase 1/2
- Safety and Efficacy of AM712 in Patients with NAMDCompletedNCT05345769Phase 1
- A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)CompletedNCT05345236Phase 3
- M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMDCompletedNCT05324150
- An Observational Study of the Progression of Intermediate Age-Related Macular DegenerationActive, not recruitingNCT05300724
- A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMDStatus unknownNCT05297292Phase 2/3
- Ocular Coherence Tomography During Cataract AssessmentCompletedNCT05287269
- Pistachios and Neural Macular PigmentStatus unknownNCT05283941Not applicable
- Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification StudyCompletedNCT05281042
- Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world SettingTerminatedNCT05266495
- This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt DiseaseCompletedNCT05266014Phase 1/2
- Targeted Fluorescence Imaging in AMDCompletedNCT05262244Phase 1
- A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationActive, not recruitingNCT05230537Phase 2
- Therapy of Age-related Macular DegenerationStatus unknownNCT05222997
- Beovu Experience UZ LeuvenStatus unknownNCT05220085
- Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD RelapseCompletedNCT05211804
- Development of an Optimal Algorithm for the Management of Patients With Retinal Pigment Epithelium Detachment in Neovascular Age-related Macular Degeneration Using Artificial IntelligenceCompletedNCT05208931
- The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCTCompletedNCT05202587
- Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy StudyTerminatedNCT05200624Not applicable
- Visual Outcome After Vitrectomy With Subretinal tPA InjectionCompletedNCT05196139
- Treatment of Age-related Macular Degeneration Using Retinal Stem and Progenitor CellsStatus unknownNCT05187104Phase 1/2
- Discovering Early Biomarkers in Circulating Endothelial Cells for Diabetes Complications by Single Cell RNA SequencingCompletedNCT05169502
- Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)CompletedNCT05155293Phase 3
- Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)CompletedNCT05146687
- Clinical Study on the Efficacy and Safety of BAT5906 InjectionCompletedNCT05141994Phase 2
- A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility TrainingCompletedNCT05135195Not applicable
- High Resolution Optical Coherence TomographyStatus unknownNCT05130385
- A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular DegenerationWithdrawnNCT05126966Phase 3
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal DisordersActive, not recruitingNCT05112861Phase 3
- Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical PracticeTerminatedNCT05112835
- Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)CompletedNCT05111743
- Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)CompletedNCT05110209
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy ParticipantsCompletedNCT05105607Phase 1
- Fundus Image-guided Focal Electroretinography, Usability StudyCompletedNCT05100511Not applicable
- VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization DiseasesActive, not recruitingNCT05099094Early Phase 1
- OcuDyne System in the Treatment of AMDCompletedNCT05091476Not applicable
- Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)CompletedNCT05082415
- Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services ProgramCompletedNCT05066685
- Impact of Regular Consumption of Grapes on Eye Health in Singapore Older AdultsActive, not recruitingNCT05064865Not applicable
- A Study to Evaluate the Safety and Efficacy of RQC for AMDCompletedNCT05062486Phase 2
- Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.Status unknownNCT05056025Not applicable
- Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular DegenerationTerminatedNCT05038371
- Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of BroluciumabCompletedNCT05037396
- Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular DegenerationStatus unknownNCT05005884Phase 1
- Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDCompletedNCT05003245Phase 3
- Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMDCompletedNCT04993352Phase 1/2
- Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular DegenerationCompletedNCT04989699Phase 1
- Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.CompletedNCT04988178
- Reading Speed Improvements in Wet-AMD Patients After Ranibizumab TreatmentCompletedNCT04982484
- Optimising Visual Acuity Measurement in Macular DegenerationCompletedNCT04920071
- Study of SCB-420 in Subjects With Neovascular Age-related Macular DegenerationWithdrawnNCT04919096Phase 1
- Home OCT Fluid Visualization Agreement StudyStatus unknownNCT04907409
- QA102 Phase 1 Study in Healthy Young and Older Adult SubjectsCompletedNCT04894071Phase 1
- Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU BrugmannCompletedNCT04891835
- Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMDCompletedNCT04884399Phase 1
- BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular DegenerationStatus unknownNCT04882956Not applicable
- Telemedicine in Age-Related Macular DegenerationStatus unknownNCT04863391
- A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular DegenerationCompletedNCT04857177Phase 3
- Non-Responsive Diabetic Macular Edema and SpironolactoneWithdrawnNCT04853355Phase 4
- Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved IndicationsCompletedNCT04847895
- Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for ExclusionCompletedNCT04836143
- RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT04832724Phase 2
- A Study of IBI302 in Patients With nAMDCompletedNCT04820452Phase 2
- Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular DegenerationActive, not recruitingNCT04796545Not applicable
- Online Validation of Dietary Intake Food Frequency Questionnaire Over Four Weeks, and Electronic Device Use Questionnaire Over Eight Weeks.CompletedNCT04779411
- Association of MPOD Values With Blue Light.CompletedNCT04779398
- Macula Evolution in Patients With AMD Taking Oral Food SupplementationCompletedNCT04778436Not applicable
- Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy OutcomesCompletedNCT04776031Not applicable
- Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in PortugalTerminatedNCT04764656
- FLIO and the Influence of Oral Lutein Supplementation on Macular PigmentCompletedNCT04761341Phase 4
- Study of Nutritional Supplementation in Patients With Unilateral Wet AMDCompletedNCT04756310Not applicable
- First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)CompletedNCT04747197Phase 1
- ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular DegenerationCompletedNCT04744662Phase 1
- "Night Vision and Carotenoids"CompletedNCT04741763Not applicable
- A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDCompletedNCT04740671Phase 3
- Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus PhotographCompletedNCT04723160
- Comparing Vision Tests in a Virtual Reality Headset to Existing AnaloguesCompletedNCT04714424
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDActive, not recruitingNCT04704921Phase 2/3
- Brolucizumab vs. Aflibercept for Retinal Angiomatous ProliferationWithdrawnNCT04698850Phase 4
- Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)WithdrawnNCT04697953Phase 3
- Observational Study of Vision Improvement in Patients With Retinal DisordersCompletedNCT04693702